Contact our experts today
Composed of proven experts from the pharmaceutical industry, our team is ready to answer to your needs in any area of product development, commercialisation and early access programs, and life cycle management
BlueReg was involved in the review of a Hybrid Application for a medicinal product in Ophthalmology to be submitted to the European Medicines Agency (EMA).
BlueReg reviewed the Module 3 (Quality) as well as the Quality Overall Summary (QOS), Non-Clinical Overview and Clinical Overview, to determine if they contained sufficient relevant evidence to support a Hybrid Application. BlueReg also reviewed the legal basis for validation of the Hybrid Application status in Module 1 of the dossier.
Thank you for your interest in BlueReg
The file will be sent to you by email.